Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | GLA | P06280 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | CYP11B1 | P15538 | 6/20 | 0.52 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.44 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.44 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6505265 | 1.00 | POLB (0.60) | POLBGLAALDH1A1MAPTCYP11B1 | |
| SCHEMBL7378793 | 0.84 | POLB (0.58) | POLBGLAALDH1A1MAPTCYP11B1 | |
| SCHEMBL11237579 | 0.81 | TSHR (0.53) | POLBGLAALDH1A1MAPTTSHR | |
| SCHEMBL11237581 | 0.81 | TSHR (0.53) | POLBGLAALDH1A1MAPTTSHR | |
| SCHEMBL1404594 | 0.81 | POLB (0.61) | POLBGLAALDH1A1MAPTCYP11B1 | |
| SCHEMBL1404593 | 0.81 | POLB (0.61) | POLBGLAALDH1A1MAPTCYP11B1 | |
| SCHEMBL10516101 | 0.81 | GLA (0.59) | POLBGLAALDH1A1MAPTCYP11B1 | |
| SCHEMBL3126651 | 0.81 | GLA (0.58) | POLBGLAALDH1A1MAPTCYP11B1 | |
| SCHEMBL3126653 | 0.81 | GLA (0.58) | POLBGLAALDH1A1MAPTCYP11B1 | |
| SCHEMBL25796691 | 0.80 | CYP11B1 (0.57) | POLBGLAALDH1A1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7297708-B2 | Heteroaromatic substituted cyclopropane as corticotropin releasing hormone ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-20 | — | — | US | disclosed |
| US-6958341-B2 | Pyrazolopyrimidines as CRF antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-10-25 | — | — | US | disclosed |
| US-20030229091-A1 | Heteroaromatic substituted cyclopropane as corticotropin releasing hormone ligands | BRISTOL-MYERS SQUIBB COMPANY | 2003-12-11 | — | — | US | disclosed |
| US-20030139426-A1 | Pyrazolopyrimidines as CRF antagonists | WILDE RICHARD G (US) | 2003-07-24 | — | — | US | disclosed |
| WO-2000059908-A2 | PYRAZOLOPYRIMIDINES AS CRF ANTAGONISTS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229091-A1 | Heteroaromatic substituted cyclopropane as corticotropin releasing hormone ligands | CRHR1, CRH, CRHR2 | POLB 4467/4885GLA 4656/4885ALDH1A1 2218/4885 |
| US-20030139426-A1 | Pyrazolopyrimidines as CRF antagonists | CRHR1, CRHR2, CRH | POLB 3931/4885GLA 4861/4885ALDH1A1 852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.